...
首页> 外文期刊>Acta Biochimica Polonica >Development of novel cellular model for affinity studies of histamine H_4 receptor ligands*
【24h】

Development of novel cellular model for affinity studies of histamine H_4 receptor ligands*

机译:用于组胺H_4受体配体亲和研究的新型细胞模型的开发*

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The G protein-coupled histamine H_4 receptor (H_4R) is the last member of histamine receptors family discovered so far. Its expression pattern, together with postulated involvement in a wide variety of immunological and inflammatory processes make histamine H_4 receptor an interesting target for drug development. Potential H_4R ligands may provide an innovative therapies for different immuno-based diseases, including allergy, asthma, pruritus associated with allergy or autoimmune skin conditions, rheumatoid arthritis and pain. However, none of successfully developed selective and potent histamine H_4 receptor ligands have been introduced to the market up to date. For that reason there is still a strong demand for pharmacological models to be used in studies on potent H_4R ligands. In current work we present the development of novel mammalian cell line, stably expressing human histamine H_4 receptor, with use of retroviral transduction approach. Obtained cell line was pharmacologically characterized in radioligand binding studies and its utility for affinity testing of potent receptor ligands was confirmed in comparative studies with the use of relevant insect cells expression model. Obtained results allow for statement that developed cellular model may be successfully employed in search for new compounds active at histamine H_4 receptor.
机译:G蛋白偶联的组胺H_4受体(H_4R)是迄今为止发现的组胺受体家族的最后一个成员。它的表达模式,以及假定的参与各种免疫和炎症过程的结合,使组胺H_4受体成为药物开发的有趣目标。潜在的H_4R配体可为不同的基于免疫的疾病(包括过敏,哮喘,与过敏或自身免疫性皮肤病相关的瘙痒症,类风湿关节炎和疼痛)提供创新的疗法。然而,迄今为止,尚未成功开发出成功开发的选择性和有效的组胺H_4受体配体。因此,仍然强烈需要用于有效H_4R配体研究的药理模型。在当前的工作中,我们提出了使用逆转录病毒转导方法稳定表达人组胺H_4受体的新型哺乳动物细胞系的开发。在放射性配体结合研究中对获得的细胞系进行了药理学表征,并在使用相关昆虫细胞表达模型的比较研究中证实了其可用于有效受体配体的亲和力测试。获得的结果表明,发达的细胞模型可以成功用于寻找对组胺H_4受体有活性的新化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号